Bausch + Lomb Corporation delivered a textbook execution quarter on July 29, 2026, but the more consequential story sits one layer above the P&L. The eye health specialist posted second-quarter revenue of $1.394 billion, up 9% reported and 8% on a constant currency basis, with both Pharmaceuticals and Surgical clearing double-digit growth and Vision Care grinding out a steady mid-single-digit gain. GAAP net loss attributable to the company narrowed sharply to $(14) million from $(62) million a year ago, while Adjusted EBITDA, a non-GAAP profitability measure defined as earnings before interest, taxes, depreciation and amortization with various acquisition, restructuring and stock-compensation add-backs, climbed to $241 million from $191 million. The board simultaneously raised full-year 2026 revenue guidance to $5.440 billion to $5.540 billion and Adjusted EBITDA excluding acquired in-process R&D, a non-GAAP add-back for upfront payments to in-licence research programs that have not yet reached commercialisation, to $1.025 billion to $1.075 billion, both higher than the ranges set in late April.
The deeper read sits on the corporate-governance tape. On August 6, 2026 the company disclosed that controlling shareholder Bausch Health Companies Inc. (BHC), which has held a majority stake since the May 2022 IPO and now owns roughly 87% of outstanding common shares, requested the appointment of four new directors including BHC chief executive Thomas J. Appio. The reshuffle, which swaps out four independent directors, is a mechanical step in a separation that management has been telegraphing for several quarters and is consistent with the 2022 IPO carve-out thesis: BLCO trades as a public eye-health pure-play while BHC retains the legacy specialty pharmaceutical, gastrointestinal and aesthetics assets plus a multi-year debt load. For minority shareholders, the question is no longer whether BLCO stands alone, but on what terms and at what share price.
Our interpretation is that the quarter is more important as a feasibility signal than as a single-period beat. Premium intraocular lens (IOL) revenue grew 175% reported, lifting premium to 13% of the Surgical segment from 6% in 2025, while MIEBO and XIIDRA, the two flagship dry-eye and dry-eye-adjacent pharmaceutical franchises, together delivered 27% combined revenue growth in the first half of 2026. Those two product stories, plus the modest but durable growth of Biotrue ONEday and ULTRA monthly contact lenses, are the mix shift that justifies a re-rating if the BHC overhang is removed cleanly. The single load-bearing risk is separation execution: a BHC spin or exchange offer that prices BLCO at a high multiple absorbs scarce equity into an already-elevated base, while a poorly timed exchange into BHC's still-elevated debt stack would compress BLCO's independent multiple. The next test is the third-quarter print in late October, where management's first full quarter under the re-shaped board, and any incremental disclosure on a BHC distribution path, are the clocks that either confirm or puncture the thesis.